Enterprise Value

1.43B

Cash

318M

Avg Qtr Burn

N/A

Short % of Float

22.57%

Insider Ownership

1.60%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Symproic (naldemedine) Details
Opioid induced constipation, Bowel preparation

Approved

Quarterly sales